Concepedia

Author

Beverly A. Teicher

Dana-Farber Cancer InstituteORCID

Also Known As

B A Teicher, B Teicher, B. A Teicher, B. A. TEICHER, B. A. Teicher, B. Teicher, B.A. TEICHER, B.A. Teicher, BEVERLY A. TEICHER, Bagley, Rebecca G

837

Publications

24.9K

Citations

76

H-Index

179

Concepts

All Affiliations

Dana-Farber Cancer InstituteNational Cancer InstituteHarvard UniversityEli Lilly (United States)Center for Cancer Research
BA

About

Beverly A. Teicher is an author at Dana-Farber Cancer Institute specializing in medicine, tumor biology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

58

167

11.8K

2

Health Sciences

23

31

2.2K

3

Natural Sciences

16

19

1.6K

4

Biochemistry

16

19

1.5K

5

Engineering

9

9

588

Beverly A. Teicher

×

255

Publications

17.7K

Citations

66

H-Index

YearCitations

Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib

Junko Murai, Shar-yin N. Huang, Amèlie Renaud,

Molecular Cancer Therapeutics

2013

745

Overexpression of Metallothionein Confers Resistance to Anticancer Drugs

Susan L. Kelley, Alakananda Basu, Beverly A. Teicher,

Science

1988

604

Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells.

Beverly A. Teicher, John S. Lazo, Alan C. Sartorelli

PubMed

1981

559

Tumor Evasion of the Immune System by Converting CD4+CD25− T Cells into CD4+CD25+ T Regulatory Cells: Role of Tumor-Derived TGF-β

Victoria C. Liu, Larry Wong, Thomas L. Jang,

The Journal of Immunology

2007

439

A Menin-MLL Inhibitor Induces Specific Chromatin Changes and Eradicates Disease in Models of MLL-Rearranged Leukemia

Andrei V. Krivtsov, Kathryn Evans, Jayant Y. Gadrey,

Cancer Cell

2019

421

Antibody Conjugate Therapeutics: Challenges and Potential

Beverly A. Teicher, Ravi Chari

Clinical Cancer Research

2011

415

A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

Karen H. Antman, Lois Ayash, Anthony Elias,

Journal of Clinical Oncology

1992

374

Comprehensive characterization of the Published Kinase Inhibitor Set

Jonathan M. Elkins, Vita Fedele, M. Szklarz,

Nature Biotechnology

2015

338

PARP Inhibitor Activity Correlates with <i>SLFN11</i> Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer

Benjamin H. Lok, Eric E. Gardner, Valentina E. Schneeberger,

Clinical Cancer Research

2016

326

Tumor Resistance to Alkylating Agents Conferred by Mechanisms Operative Only in Vivo

Beverly A. Teicher, Terence S. Herman, Sylvia A. Holden,

Science

1990

316

Page 1